NICE issues preliminary recommendation for GlivecÒ in England and Wales as first-line drug therapy for patients with chronic myeloid leukemia
Basel, Switzerland, 18 June 2003 - The National Institute for Clinical Excellence (NICE) has issued a preliminary recommendation that the Novartis drug GlivecÒ (imatinib)* should be used for first-line treatment of patients newly diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase. Glivec received a licence in the UK as part of the centralized EU license to treat newly diagnosed (Ph+) CML patients on 19 December 2002.
Please see full press release under the following link:
